aTYR PHARMA INC ATYR
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances)
Chart by TradingView
1/9
Piotroski F — financial health
-19.49
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $190,000 | -$74.1M | — | -$62.1M | $67.5M |
| 2024 | $235,000 | -$64.0M | — | -$69.2M | $69.8M |
| 2023 | $353,000 | -$50.4M | — | -$37.4M | $90.5M |
| 2022 | $10.4M | -$45.3M | — | -$43.5M | $71.3M |
| 2021 | $0 | -$33.8M | — | -$33.3M | $109.1M |
| 2020 | $10.5M | -$16.2M | — | -$15.5M | $31.5M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| SCHIMMEL PAUL | director | 2026-05-27 | Buy | 100,000 | $0.50 |
| Broadfoot Jill Marie | Chief Financial Officer | 2026-02-04 | Sell | 1,558 | $0.98 |
| Shukla Sanjay | President and CEO | 2026-02-04 | Sell | 3,745 | $0.98 |
| DENYES NANCY | General Counsel | 2026-02-04 | Sell | 1,118 | $0.98 |
| Broadfoot Jill Marie | Chief Financial Officer | 2026-02-03 | Option exercise | 3,750 | — |
| Shukla Sanjay | President and CEO | 2026-02-03 | Option exercise | 10,375 | — |
| DENYES NANCY | General Counsel | 2026-02-03 | Option exercise | 2,687 | — |
Why these scores methodology →
Piotroski F-score: 1/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -19.49 (distress)
- Working capital / assets 0.7
- Retained earnings / assets -6.518
- EBIT / assets -0.835
- Equity / liabilities 2.644
Source: SEC EDGAR filings · CIK 0001339970 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.